Report Library
All Reports
2016 Biomedtracker Post-DDW Report
June 17, 2016
The 2016 Digestive Disease Week (DDW) meeting was held in San Diego, CA on May 21-24 and Biomedtracker was in attendance. Below are a few key highlights from the meeting. We provide more thorough commentary and analyses on select presentations in the full report. We also highlight data on a new target in the world of digestion, specifically with respect to Crohn’s disease. A list of all of the
DDW events added by Biomedtracker and our sister product, Meddevicetracker, is provided at the end of the report.
Key Highlights
For our disclosures, please read the Biomedtracker Research Standards.
Key Highlights
- Plecanatide (SGYP): Updated Phase III results of plecanatide (3.0 and 6.0 mg) in patients with chronic idiopathic
constipation, who met the modified Rome III criteria for functional constipation for at least 3 months with symptoms onset for at least 6
months, demonstrated statistically significant changes in CSBMs from baseline (Plecanatide 3 mg - 2.5 events/week; Plecanatide 6 mg - 2.2 events/week).
- SYN-010 (SYN): Updated Phase II data of SYN-010 in patients diagnosed with IBS-C and breath methane levels greater
than 10 ppm at screening showed positive changes in monthly responders at Day 84 in all treatment groups (Placebo/SYN-010 42 mg -
46%; SYN-010 21 mg/SYN-010 42 mg - 47%; SYN-010 42 mg/SYN-010 42 mg - 33%).
- Stelara (JNJ): Top-line pivotal results of Stelara in moderate-to-severe patients with Crohn's disease who achieved clinical
response at Week 8 in one of two previous induction studies indicated statistically significant improvements in clinical remission at Week 44, the primary endpoint of the study (Placebo - 35.9%; Stelara 90 mg q12w - 48.8%, Stelara 90 mg q8w - 53.1%).
- ABBV-066 (ABBV): Top-line, initial Phase II results of ABBV-066 in patients with clinically active Crohn's disease confirmed by endoscopy and previously treated with a TNF antagonist of conventional CD therapy demonstrated a promising dose response between the two treatment groups, with ABBV-066 meeting the primary endpoint of the study in the 600 mg dosing group (clinical remission at Week 12).
For our disclosures, please read the Biomedtracker Research Standards.
| Disease Group Covered: |
Autoimmune/immunology
Gastroenterology (Non Inflammatory Bowel Disease) |
| Indications Covered: |
Neuromyelitis Optica (Devic's Syndrome, NMO)
Wound Healing |
Additional Resources: